Abstract: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.

Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Abstract: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.

Abstract: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.

Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Abstract: The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to bind epitopes from GM-CSF proteins of multiple species.

Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Abstract: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.

Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Abstract: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.

Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Abstract: The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to bind epitopes from GM-CSF proteins of multiple species.

Abstract: A more efficient method of improving the feel and appearance of cellulosic-containing fabric prior to finishing which method comprises contacting the fabric with a cellulase solution under pressure, and under conditions wherein the solution cascades across the fabric, and under conditions effective in improving the feel and appearance of the cellulosic-containing fabric.

Abstract: Disclosed are strength loss resistant methods for treating cotton toweling with cellulase so as to impart permanent softening to the toweling. In particular, the methods disclosed herein involve the application of a specified amount of cellulase onto one or both of the surfaces of a cotton toweling so as to result in permanent softening of the toweling.

Abstract: Disclosed are strength loss resistant methods for treating cotton toweling with cellulase so as to impart permanent softening to the toweling. In particular, the methods disclosed herein involve the application of a specified amount of cellulase onto one or both of the surfaces of a cotton toweling so as to result in permanent softening of the toweling.

Abstract: Non-dyed and non-finished cotton woven fabric is contacted with a cellulase solution with agitation under conditions so as to produce a cascading effect of the solution over the cotton woven fabric. When so conducted, the treated cotton woven fabric has improved feel and appearance characteristics as compared to the fabric prior to treatment. Additionally, such methods result in the removal of dead and immature cotton from the fabric.

Abstract: The present invention involves an improved levelling agent and a method of using it in the disperse dyeing of hydrophobic synthetic fiber materials such as polyesters and polyamides. The levelling agent enhances dye migration without substantially accelerating the exhaustion of dye onto the fabric being dyed. It is based on diaryl ethers such as ditolyl ether mixed with emulsifiers and optionally a diluent which is water or an organic solvent.It also involves a process for improving the levelness of already dyed materials by subjecting them to temperatures above the boiling point of water in the presence of diaryl ether based levelling agents.